On the cost of regulation under Solvency II

This paper shows that insurers can meet solvency requirements without a great sacrifice to the expected return either of themselves or their policyholders and thus that the regulation through Solvency II is not very costly

Regulatory authorities want to implement a new solvency framework in Europe, Solvency II. In order to meet the solvency requirement of Solvency II, life insurance companies and pension funds fear they will be unable to invest sufficiently in the equity market under the regulation of Solvency II, and will be forced to follow quite conservative risk management strategies. If this is the case, the cost of regulation subject to Solvency II is very high. Our objective is to investigate the validity

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

The new rules of market risk management

Amid 2020’s Covid-19-related market turmoil – with volatility and value-at-risk (VAR) measures soaring – some of the world’s largest investment banks took advantage of the extraordinary conditions to notch up record trading revenues. In a recent Risk.net…

ETF strategies to manage market volatility

Money managers and institutional investors are re-evaluating investment strategies in the face of rapidly shifting market conditions. Consequently, selective genres of exchange-traded funds (ETFs) are seeing robust growth in assets. Hong Kong Exchanges…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here